home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  FT Global Biotech Conference  
  June 23, 2003

Biotechnology

 
     
  The Financial Times, The Landmark Hotel, London, UK
12-13 November 2003


Programme Outline:

12 November

KEYNOTE FORUM

ANALYSING BUSINESS DIMENSIONS AND STRATEGIC DIRECTIONS
- What is the optimum business model for sustainable growth
- What is best practice in structuring co-development and co-promotion alliances?
- How will pharma and biotech relationships evolve?
- Risk assessment – what are the fundamentals of licensing agreements?
- The road to commercialisation

MECHANISMS OF FINANCE AND INVESTMENT
- Has the science met the bottom line objectives?
- The value proposition – how can the sector attract investors back to biotech?
- Alternative funding sources
- Trends and issues in venture financing

13 November

SCIENCE, INNOVATION & TECHNOLOGY
- Revolutionary advances in novel mainstream science
- Are the technology platforms really adding significant value?
- Advances in Proteomics, Genomics and other cutting edge fields of biotech
- Hot targets that everyone is looking to drug – protein kinases, signal transduction

THE GLOBAL FRAMEWORK OF BIOTECH
- Fostering competitiveness and innovation in Europe
- The value of global research collaboration
- The human proteome organisation HUPO – a global initiative
- Global opportunities

 
 
Organized by: The Financial Times
Invited Speakers: Mr Tony L White
Chairman, President and CEO
Applera Corporation

Dr Peter Fellner
Chairman
Celltech Group plc

Dr George Poste
Chief Executive Officer
Health Technology Networks

Dr William A Haseltine
Chairman and CEO
Human Genome Sciences, Inc

Prof Dr Bernd Seizinger
President and CEO
GPC Biotech AG

Mr Martyn Postle
Director
Cambridge Healthcare and Biotech

Dr Samir Hanash
President
Human Proteome Organisation HUPO

Dr Göran Ando
Group Chief Executive
Celltech Group plc

Dr Thomas Hofstaetter
Senior Vice President,
Corporate Development
Aventis

Dr Jean-Paul Clozel
CEO and Director
Actelion Ltd

Mr Steven Burrill
CEO
Burrill & Company

 
Deadline for Abstracts: Immediate
 
Registration: For further details and to register, please visit the conference website at http://www.ftconferences.com/biotech
E-mail: ftconferences@ft.com
 
  Posted by:   Juliana Akor  
Host: newsgate.ft.com
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.